Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC-01 (aripiprazole + sertraline) in major depressive disorder with inadequate response to sertraline
jRCT2080222363Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jan 2014
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing ASC-01 (aripiprazole + sertraline) with Placebo + sertraline (2 arms). Started Jan 2014; status: completed.
02
Drugs
aripiprazole + sertraline
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2080222363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222363.